What are the recent financial highlights of MARKSANS PHARMA LIMITED?

MARKSANS PHARMA LIMITED recently reported a total revenue of ₹2,474.40 Cr and a net profit margin of 14.89%. These metrics reflect the company’s consistent financial performance.

What is the dividend yield of MARKSANS PHARMA LIMITED?

MARKSANS PHARMA LIMITED offers a dividend yield of 0.29%, with a dividend rate of ₹0.6 per share.

What are the key financial metrics of MARKSANS PHARMA LIMITED?

Key financial metrics include a trailing P/E ratio of 23.332514, forward P/E of 17.706543, book value of ₹50.244, price-to-book ratio of 3.7707987, and a market capitalization of ₹85.86 billion.

What does MARKSANS PHARMA LIMITED do?

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, upper respiratory, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. It also produces a range of solid oral dosage forms, including tablets and hard gelatin capsules; soft gels; essential oils; ointments; and creams and liquids, as well as prescription drugs. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Loading...

₹ 0 0.00%

Loading... BSE: Loding... NSE: Marksans

About

Loading... ^[1]

Website BSE NSE

Market Cap ₹ 0 Cr.
Current Price ₹ 0
High / Low ₹ 0 / 0
Stock P/E
Dividend Yield 0 %
ROE 0 %
EPS 0
P/B Ratio 0
Net Profit Margin 0 %
Debt to Equity 0
ROCE 0 %
Interest Coverage 0 %

Stock News - Marksans

Latest updates related to Marksans

Sr No.	Title	Sentiment
1	Marksans Pharma Shows Resilience Amid Market Volatility with Significant Long-Term Gains MarketsMojo	🔄
2	Marksans Pharma consolidated net profit rises 25.61% in the December 2024 quarter Business Standard	🔄
3	Marksans Pharma Consolidated December 2024 Net Sales at Rs 681.85 crore, up 16.33% Y-o-Y Moneycontrol	🔄
4	Marksans Pharma shares surged 16% today. Here's why Business Today	🔄
5	Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price Simply Wall St	🔄
6	Marksans Pharma Q1 Results Live : profit rise by 29.27% YOY Mint	🔄
7	Marksans Pharma gets USFDA nod for generic allergy drug BusinessLine	🔄
8	Marksans Pharma shares climb after USFDA's nod for allergic rhinitis drug Business Standard	🔄
9	Marksans Pharma Reports Highest Net Sales and Profit in Five Quarters for December 2024 MarketsMojo	🔄
10	Marksans Pharma Standalone December 2024 Net Sales at Rs 311.87 crore, up 29.21% Y-o-Y Moneycontrol	🔄

Peer Comparison

Macro Industry: Loading.. | Sector: Loading.. | Industry: Loading.. | Basic Industry: Loading..

Loading peers table...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Loading data...

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Loading Profit & Loss data...

Compounded Sales Growth
10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth
10 Years:
5 Years:
3 Years:
TTM:

Stock Price CAGR
10 Years:
5 Years:
3 Years:
1 Year:

Return on Equity
10 Years:
5 Years:
3 Years:
Last Year:

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Shareholding Pattern

Numbers in percentages

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Loading...

Loading...

Stock News - Marksans

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Delivery Data

Insider Data

Technical Data

Static Application Security Testing

Documents

Announcements

Annual reports

Credit ratings

Concalls

Explore More Stocks